0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > ROR2

ROR2

Brief Information

Name:Tyrosine-protein kinase transmembrane receptor ROR2
Target Synonym:EC:2.7.10.1,ROR2,NTRKR2,Receptor Tyrosine Kinase Like Orphan Receptor 2,Tyrosine-Protein Kinase Transmembrane Receptor ROR2,Neurotrophic Tyrosine Kinase, Receptor-Related 2,Neurotrophic Tyrosine Kinase Receptor-Related 2,Receptor Tyrosine Kinase-Like Orphan Receptor 2,EC 2.7.10.1,BDB1,BDB
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

RO2-H52E5-ELISA
 ROR2 ELISA

Immobilized Human ROR2, His Tag (Cat. No. RO2-H52E5) at 1 μg/mL (100 μL/well) can bind Anti-ROR2 Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

RO2-M52H3-MALS-HPLC
ROR2 MALS images

The purity of Mouse ROR2 Protein, His Tag (Cat. No. RO2-M52H3) is more than 85% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.

Synonym Name

ROR2,NTRKR2

Background

Tyrosine-protein kinase transmembrane receptor ROR2 is also known as Neurotrophic tyrosine kinase, receptor-related 2 (NTRKR2), which belongs to the protein kinase superfamily and Tyr protein kinase family and ROR subfamily. ROR2 is a homodimer protein, which can binds YWHAB or interact with WTIP. ROR2 may be involved in the early formation of the chondrocytes. It seems to be required for cartilage and growth plate development.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CCT301-59 CCT301-59 Phase 2 Clinical Bioatla, F1 Oncology Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Sarcoma Details
Ozuriftamab Vedotin CAB-ROR2; CAB-ROR2-ADC; CAB-ADC; BA-3021; HTBA-3021 Phase 2 Clinical Bioatla Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
CCT301-59 CCT301-59 Phase 2 Clinical Bioatla, F1 Oncology Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Sarcoma Details
Ozuriftamab Vedotin CAB-ROR2; CAB-ROR2-ADC; CAB-ADC; BA-3021; HTBA-3021 Phase 2 Clinical Bioatla Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop

Laisser un message